Trevi Therapeutics, Inc. Cash and Restricted Cash
Trevi Therapeutics, Inc. (TRVI) had Cash and Restricted Cash of $54.30 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.30M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.41M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.91M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56.87M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $54.30M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $19.41M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $18.91M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $56.87M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $117.06M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $19.37M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $34.10M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $16.05M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $12.96M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $13.81M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $32.40M 10-K · filed 2026-03-17 |
| 2023-09-30 | $25.96M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $13.75M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $11.65M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $12.59M 10-K · filed 2025-03-18 |
| 2022-09-30 | $66.57M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $24.70M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $29.11M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $36.83M 10-K · filed 2024-03-20 |
| 2021-09-30 | $29.32M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $36.42M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $41.57M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $45.00M 10-K · filed 2023-03-16 |
| 2020-09-30 | $53.29M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $44.18M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $52.64M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $57.31M 10-K · filed 2022-03-17 |
| 2019-09-30 | $63.52M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $71.39M 10-Q · filed 2020-08-13 |
| 2019-03-31 | $12.95M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $7.20M 10-K · filed 2021-03-25 |
| 2017-12-31 | $22.02M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |